Back to search results

Early Phase Trial of RPTR-1-201 for Advanced Solid Tumors

This early-phase study is testing a new drug called RPTR-1-201 for adults with advanced solid tumors that cannot be cured with standard treatments. Researchers want to see how safe RPTR-1-201 is, how well your body tolerates it, and if it shows any signs of shrinking tumors. The study will test RPTR-1-201 by itself and in combination with another type of cancer drug called a PD-1/PD-L1 monoclonal antibody. To join, you must have advanced solid tumors, at least one measurable tumor, and good overall health. The study will look at side effects and how many participants experience tumor shrinkage.

Study design
This is an early phase interventional study planning to enroll 150 participants. It will evaluate RPTR-1-201 as a single treatment and in combination with another drug.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Safety will be monitored through 30 days after your last dose. Tumor response will be assessed until the end of treatment or documented disease progression, up to 24 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07293754

An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors

Recruiting
PHASE1Ages 18+InterventionalTreatment
Repertoire Immune Medicines
~150 participants
Updated 2026-02-17 on ClinicalTrials.gov
What's tested:RPTR-1-201PD-1 / PD-L1 monoclonal antibody

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of participants with dose-limiting toxicities and treatment-emergent adverse events.
Measured over From first dose through 30 days after last dose of trial treatment.
+1 more outcome measured

Conditions

Advanced Malignant Solid Tumor

Explore related trials

Solid Neoplasm

NCT07293754

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • START Midwest

    Grand Rapids, Michiganstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Jacob Goldberg
[email protected]
616-954-5561
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Histologically or cytologically confirmed locally advanced or metastatic solid tumors that is not amenable to curative treatment.
At least one measurable lesion per RECIST v1.1 as assessed by the investigator.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Adequate organ function as defined in the trial protocol.
Ability to provide written informed consent and comply with trial procedures.

Exclusion

History of another malignancy within 3 years before the first dose of trial intervention, with the exception of malignancies considered cured and not expected to require active therapy (for example, certain skin cancers or in situ malignancies) per protocol.
Known active leptomeningeal disease or uncontrolled central nervous system metastases.
Active, clinically significant, autoimmune diseases requiring systemic immunosuppressive therapy.
Prior allogenic organ transplantation
Clinically significant uncontrolled medical or psychiatric condition, that in the opinion of the investigator, would increase risk or interfere with trial participation.

What this trial measures

  • Number of participants with dose-limiting toxicities and treatment-emergent adverse events.From first dose through 30 days after last dose of trial treatment.

    Number of participants experiencing dose-limiting toxicities and treatment-emergent adverse events, including events considered related to RPTR-1-201, graded according to CTCAE v5.0.

  • Objective Response Rate (ORR) per RECIST v1.1From first dose until end of treatment or documented disease progression, whichever occurs first (assessed up to 24 months).

    Proportion of participants with a best overall response of complete response or partial response per RECIST v1.1, as assessed by the investigator.